Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder
NCT ID: NCT03371342
Last Updated: 2019-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
30 participants
INTERVENTIONAL
2017-12-13
2018-09-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacodynamic and Safety of MEDITOXIN® in Healthy Male Volunteers
NCT03317717
Evaluate the Safety and Efficacy of Botulax® Versus Botox® in Patient With Overactive Bladder
NCT04186442
Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder
NCT05463822
Over Active Bladder Instillation Study - Botox
NCT00667095
Botulin-A Toxin Instillations and Overactive Bladder
NCT00583219
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MEDITOXIN
Meditoxin
Meditoxin (Botulinum toxin type A)
BOTOX
Botox
Botox(Botulinum toxin type A)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Meditoxin
Meditoxin (Botulinum toxin type A)
Botox
Botox(Botulinum toxin type A)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject who has symptoms of Overactive Bladder for a period of at least 6 months immediately prior to screening
Exclusion Criteria
20 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medy-Tox
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asan Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MT01-KR17OAB101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.